patritumab
daiichi sankyo
['patritumab', 'mbc', 'breast']
abstract presentation 3 is now live: ian e. krop, md, phd with results from the phase 1/2 study of patritumab deruxtecan, a her3-directed antibody-drug conjugate (adc), in patients with her3-expressing metastatic breast cancer (mbc) #asco22 
https://t.co/UwVNWBw7PM is a A 501(c)3 nonprofit providing education, community, & resources to those diagnosed with #breastcancer.